B. Randlev

发表

Phase I–II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas

J. Sloan, J. Sloan, E. Galanis, 2005, Gene Therapy.

Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial

A. Venook, R. Warren, D. Kirn, 2001, Gene Therapy.

The effect of azelastine on neutrophil and eosinophil generation of superoxide.

W. Busse, J. Sedgwick, B. Randlev, 1989, The Journal of allergy and clinical immunology.

Phase I I T rial o f I ntratumoral A dministration o f O NYX- 015, a R eplication-Sele ctive A denovirus, i n P atients W ith Refractory H ead a nd N eck C ancer

F. Khuri, J. Nemunaitis, E. Vokes, 2001 .

Effect of Nedocromil Sodium on the β-Adrenergic Response of Human Polymorphonuclear Leucocytes

W. Busse, A. Ruoho, B. Randlev, 2012, Drugs.

Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints.

L. Wein, D. Sze, E. Galanis, 2002, Cancer research.

Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity

J. Nemunaitis, G. Netto, D. Kirn, 2001, Gene Therapy.

Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial.

F. Khuri, J. Nemunaitis, I. Ganly, 2000, Cancer research.

A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

I. Tannock, F. Khuri, W. Hong, 2000, Nature Medicine.

Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer.

F. Khuri, J. Nemunaitis, E. Vokes, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients

J. Nemunaitis, G. Netto, L. Post, 2003, Cancer Gene Therapy.

Novel Caprine Adeno-Associated Virus (AAV) Capsid (AAV-Go.1) Is Closely Related to the Primate AAV-5 and Has Unique Tropism and Neutralization Properties

C. Scallan, Shangzhen Zhou, P. Colosi, 2005, Journal of Virology.

Phase II Tria l o f Intratumoral Adminis trat ion of ONYX-015 , a Repl icat ion-Select i ve Adenovirus , in Pat ients With Refractory Head and Neck Cancer

F. Khuri, J. Nemunaitis, E. Vokes, 2000 .

Validation of a quantitative flow cytometer assay for monitoring HER-2/neu expression level in cell-based cancer immunotherapy products.

B. Randlev, M. Marcus, A. Lin, 2010, Biologicals : journal of the International Association of Biological Standardization.